Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Repligen Corporation Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40.03 (market cap $135.56M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 82.2× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Repligen Corporation Common Stock for 0 Days on average.
| GPTY | RGEN | |
|---|---|---|
Market Cap | $135.56M | $11.14B |
Volume | 66,044 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $194.57 |
52-Week Low | $34.73 | $102.87 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
